[Safety Evaluation of Paclitaxel Injection NK in Tri-Weekly Administration of Paclitaxel plus Carboplatin(TC Therapy) for Gynecological Cancers].

Paclitaxel is a key drug used for the treatment of gynecological cancers, breast cancer, and gastric cancer. While there is a great deal of safety information on the weekly administration of generic paclitaxel NK(paclitaxel injection NK)and proprietary paclitaxel(Taxol®injection), little is known about their safety when administered tri-weekly, partly due to a small sample size. Therefore, to gain more information and to validate the safety of using generic paclitaxel NK in a tri-weekly regimen, we investigated the incidences of adverse events in response to it in a larger number of patients. The incidence of constipation was found to be higher in response to all grades of generic paclitaxel NK, with significant differences between the various grades. The profiles of other adverse events, however, were not significantly different. Thus, generic paclitaxel NK is as safe as the proprietary paclitaxel for tri-weekly administration.